Folixate™ (Folic Acid, Vitamin D3 Tablet) Rx Only

Manufacturer
PureTek Corporation
Effective date
2023-12-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:56:02

Label at a glance#

ProductFolixate
Active ingredientLEVOMEFOLATE CALCIUM, VITAMIN D
Label structure10 sections

Indications and uses

Folixate ™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation. Folixate™ can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.

Dosage and administration

Take one tablet daily or as directed by a licensed healthcare practitioner.

Storage and handling

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect from heat, light and moisture. Tamper Evident: Do not use if seal is broken or missing.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Folixate™ is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation due to Vitamin D deficiency.

Folixate™ should be administered under the supervision of a licensed healthcare practitioner.


Each tablet contains:
Folate (as L-5-Methyltetrahydrofolate calcium salt)......1700 mcg DFE
(1000 mcg of L-5-methylfolate)
Vitamin D3 (as Cholecalciferol)………....................125 mcg (5000 IU)


Each tablet contains the following inactive ingredients: Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate, Vegetable Stearic Acid.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Folixate™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation.

Folixate™ can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The in vivo synthesis of the major biologically active metabolites of Vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules.

There is a time lag of 10 to 24 hours between the administration of Vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folixate™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of Vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits. Folate alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folate in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Allergic sensitization has been reported following both oral and parenteral administration of folate.


You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Take one tablet daily or as directed by a licensed healthcare practitioner.

HOW SUPPLIED

HOW SUPPLIED SECTION

Folixate™ Tablets are supplied as round, light yellow tablets with one side scored, the other side plain and dispensed in child-resistant bottles of 30 tablets (NDC 59088-301-54).

* This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels (AUG 2, 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of B12 deficiency (pernicious anemia). Based on our assessment of the risk of obscuring pernicious anemia, this product requires licensed healthcare practitioner supervision, an Rx status, and a National Drug Code (NDC) or similarly-formatted product code, as required by pedigree reporting requirements and supply-chain control as well as in some cases, for insurance-reimbursement applications.

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.

STORAGE

STORAGE AND HANDLING SECTION

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect from
heat, light and moisture.

Tamper Evident: Do not use if seal is broken or missing.

Folixate™

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LabelLabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2671090cholecalciferol 125 MCG (5000 UNT) / levomefolate calcium 1000 MCG Oral TabletPSN1
2671097Folixate 125 MCG (5000 UNT) / 1000 MCG Oral TabletPSN1
2671097cholecalciferol 0.125 MG / levomefolate calcium 1 MG Oral Tablet [Folixate]SBD1
2671090cholecalciferol 0.125 MG / levomefolate calcium 1 MG Oral TabletSCD1
2671090cholecalciferol 5000 UNT / levomefolate calcium 1000 MCG Oral TabletSY1
2671097Folixate (cholecalciferol 5000 UNT / levomefolate calcium 1000 MCG) Oral TabletSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CHOLECALCIFEROL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
LEVOMEFOLIC ACID Pharmacologic Class Indexing1Indexing - Pharmacologic Class20230428

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
ddff2484-d547-4e6a-bacd-95eef7e31c64Product name220180807
90854981-3820-4bc4-a1d3-666ec508941cProduct name220180214
60c52429-fcef-eb54-2387-43bc9e4f296bProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
59088-301-54Folixate30 in 1 BOTTLE, PLASTICTABLET301

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
59088-301FOLIXATE (FOLATE, VITAMIN D3) TABLET [PURETEK CORPORATION]1Current NDC, 1 package rows20231207_0bb91f61-b61b-c894-e063-6394a90ae51c.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
59088-301-54EA - Each59088-3011ea4bd1b-ec81-450b-b3fa-7c1c13adc0d912024-01-04

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
59088-30159088-301-54

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FolixateFOLATE, VITAMIN D3PureTek Corporation0bb91f61-b61b-c894-e063-6394a90ae51c2023-12-05Warnings, Adverse reactionsExact identifier
ndc (package): 59088-301-54
ndc (product): 59088-301
ndc11 (package): 59088030154
spl id: 0bb91f61-b61a-c894-e063-6394a90ae51c
spl set id: 0bb91f61-b61b-c894-e063-6394a90ae51c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.